Our Summary

This research paper is a review and analysis of other studies that examined the use of magnetic resonance imaging (MRI) and targeted biopsies to detect serious prostate cancer in men who initially showed low-risk signs. The study found that a combined approach of using MRI and targeted biopsies alongside traditional methods (transrectal ultrasonography-guided biopsies) was effective in identifying more serious cancers. However, it also found that both the MRI-targeted biopsies and the traditional methods missed some cases. Therefore, the researchers recommend using both methods together to maximize detection. They also found that men with a positive MRI result were more likely to have their cancer upgraded (found to be more serious) compared to men with a negative MRI result.

FAQs

  1. What was the main finding of this research paper on prostate cancer detection?
  2. How can the detection of serious prostate cancer be maximized according to the researchers?
  3. What is the correlation between a positive MRI result and the severity of prostate cancer according to the study?

Doctor’s Tip

A doctor might tell a patient undergoing a prostate biopsy to discuss with their healthcare provider the possibility of incorporating MRI and targeted biopsies in addition to traditional methods to increase the likelihood of detecting serious prostate cancer. They may also advise the patient to follow up closely with their healthcare provider for any necessary follow-up tests or treatment based on the biopsy results.

Suitable For

Patients who are typically recommended for a prostate biopsy include those with elevated levels of prostate-specific antigen (PSA), abnormal digital rectal exam findings, or other signs and symptoms of prostate cancer. Additionally, patients who have a family history of prostate cancer or other risk factors may also be recommended for a biopsy. In the case of the research paper mentioned above, men who initially showed low-risk signs but had a positive MRI result were recommended for a targeted biopsy to further investigate the presence of serious prostate cancer.

Timeline

Before prostate biopsy:

  • Patient may experience symptoms such as frequent urination, difficulty urinating, blood in urine or semen, or pain in the lower back, hips, or pelvis.
  • Patient may undergo a digital rectal exam (DRE) to check for abnormalities in the prostate.
  • Patient may undergo blood tests to measure levels of prostate-specific antigen (PSA) to screen for prostate cancer.
  • If results of DRE or PSA test are concerning, patient may be referred for a prostate biopsy.

After prostate biopsy:

  • Patient may experience side effects such as blood in urine or semen, pain or discomfort in the rectum or pelvis, or difficulty urinating for a few days after the procedure.
  • Results of the biopsy, including the presence of cancer and the grade or stage of the cancer, are typically available within a week or two.
  • If cancer is detected, patient may undergo further tests such as imaging scans to determine the extent of the cancer and develop a treatment plan.
  • Depending on the results of the biopsy, patient may undergo active surveillance, surgery, radiation therapy, hormone therapy, or other treatments.

What to Ask Your Doctor

  1. Can you explain the reasons why a prostate biopsy is recommended in my case?

  2. What are the potential risks and side effects of a prostate biopsy?

  3. How accurate are the results of a prostate biopsy in detecting prostate cancer?

  4. What is the difference between a traditional transrectal ultrasound-guided biopsy and a targeted MRI-guided biopsy?

  5. How will the results of the biopsy impact my treatment options?

  6. If the biopsy results are negative, does that mean I do not have prostate cancer?

  7. What should I expect during and after the biopsy procedure?

  8. How long will it take to receive the results of the biopsy?

  9. What follow-up care or monitoring will be needed after the biopsy?

  10. Are there any alternative options to a prostate biopsy that I should consider?

Reference

Authors: Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ. Journal: BJU Int. 2018 Dec;122(6):946-958. doi: 10.1111/bju.14358. Epub 2018 Jun 6. PMID: 29679430